38,000 patients.
No order. No prioritization.

Just noise in the queue.

Artemis Risk Stratification

Sorted in 4.2 seconds.

Every patient assigned to an evidence-based tier. No manual review required.

Tier A
0
Immediate intervention
Uncontrolled chronic disease, high ED risk
Tier B
0
Screening eligible — missed
Guideline-eligible. Highest preventable risk.
Tier C
0
Monitor & engage
Stable but approaching eligibility thresholds
Tier D
0
Routine population
No near-term actionable gaps identified

Maria Chen, 64.

Eligible for lung cancer screening since 2022. Never screened.

HealthOS EHR — Chen, Maria A. — MRN 4781-2099
Chen, Maria A. — MRN 4781-2099
Dr. K. Yamada · Stanford Health Care
Summary
Progress Notes
Orders
Results
Med List
Problems
Hypertension
Hyperlipidemia
GERD
Medications
Lisinopril 10mg
Atorvastatin 20mg
Omeprazole 20mg
Allergies
Penicillin — rash
Chen, Maria A.
DOB: 04/11/1962 (64 yrs)
MRN: 4781-2099
PCP: Dr. K. Yamada
Insurance: Medicare Advantage
Vitals — 2024-03-14
Blood Pressure
128/82 mmHg
Heart Rate
74bpm
BMI
26.1kg/m²
SpO₂
97%
Social History
Tobacco Use
Former smoker, quit ~2019
Pack-Years
Not calculated
LDCT Screening
No order on file
Alcohol
Social, <1 drink/wk
Progress Note — 2024-03-14 · Dr. K. Yamada
Encounter: Office visit, established patient  |  Signed: 2024-03-14 15:42  |  Duration: 20 min
Patient presents for routine 6-month follow-up. Reports feeling well, no new complaints. BP 128/82 mmHg. Medications reviewed and reconciled.

Tobacco history discussed — patient reports a significant smoking history and states she stopped several years ago. No specific duration or quantity documented at this visit. No respiratory complaints.

Lipid panel reviewed; LDL 95 on atorvastatin, stable. Continue current management. Follow up in 6 months or PRN.
Pack-year history not quantified. Rules-based screening cannot determine eligibility. The information exists — it just needs to be asked.
Artemis — Stanford Health Care · Pop Health
Priority QueueTier B · 847
Showing 1–15 of 847
PatientRisk SignalTime SensitivityReachabilityPriority ScoreTier
Chen, Maria · 64F Smoking hx, pack-yrs unquantified · LDCT overdue 2yr HighCall preferred
9.2
 B
Maria Chen, 64F
MRN 4781-2099 · Dr. K. Yamada · Medicare Advantage
Tier BPHI encryptedLDCT overdue 2yrCall preferred · SDM requires voice
AI Signal Extraction
Smoking history noted, pack-years not quantified — note 2024-03-14
unstructured NLP
No LDCT order in 24-month lookback
structured orders
Age 64, female — USPSTF 2021 eligibility window open if ≥ 20 pack-years
demographics + guidelines
Missing Information
Pack-year history unquantified. USPSTF 2021 requires ≥ 20 pack-years for LDCT eligibility. Cannot confirm without direct patient confirmation.
USPSTF 2021 Grade B · CMS NCD 210.14
Recommended Workflow
1Maya conducts AI-led SDM call — full CMS NCD 210.14 script
2Patient may request J. Torres, RN live — RN joins, answers clinical questions
3Pack-years calculated, eligibility confirmed, patient consent captured
4Artemis auto-drafts incident-to SDM note for Dr. K. Yamada
5Dr. K. Yamada signs note + LDCT order — G0296 billed
BAA active · Zero PHI leaves perimeter
Stanford Health Care
Maya
AI Navigator · Outbound
M
0:00
Live Call Transcript
CMS NCD 210.14 · SDM Encounter · Maria Chen, 64
Recording & documenting
1 · Consent
2 · Identity
3 · Smoking Hx
4 · Benefits
5 · Decision
6 · PCP Order
7 · Scheduling
✓Pack-years: 23 — eligible
✓Benefits & harms reviewed
✓Radiation Q → Jamie (RN)
✓Patient decision: proceed
✓RN handoff: scheduling confirmed
Derivation Engine
Calculating in background
Artemis — LDCT Scheduling · Radiology
Radiology — Week of Sept 30
Artemis scheduling LDCT · Maria Chen
Constraint Resolution
LDCT Confirmed
Stanford Radiology · Low-Dose CT
October 3, 2024 · 9:30 AM
Stanford Health Care, Palo Alto
LDCT lung cancer screening · 20 min
USPSTF Grade B · Medicare covered
Artemis — Shared Decision-Making · CMS NCD 210.14
Shared Decision-Making Encounter
Maya AI-led · J. Torres, RN validated · Incident-to · CMS NCD 210.14
CMS NCD 210.14 — Required SDM Elements
1. Confirmed ≥ 20 pack-year smoking history (USPSTF 2021)
✓
2. Current smoker or quit within the past 15 years
✓
3. Benefits, limitations, and follow-up care discussed
✓
4. Patient agrees to continue annual screening if eligible
✓
J. Torres, RN — SDM Validated & Approved
Navigator reviewed AI-gathered documentation and confirms all CMS NCD 210.14 elements are satisfied. G0296 billing trigger armed. The AI role was pre-structuring information — the billable SDM encounter is validated by the human navigator.
SDM Encounter Note — Auto-drafted by Artemis
Lung cancer screening counseling and shared decision-making service furnished by J. Torres, RN (Care Navigator) under direct supervision of Dr. K. Yamada using AI-assisted decision support and a CMS-compliant decision aid. Eligibility, benefits/harms, false-positive risk, radiation exposure, follow-up testing, overdiagnosis, annual adherence, and willingness to undergo diagnosis and treatment were reviewed. Patient elected to proceed with LDCT.

Signed: J. Torres, RN · Care Navigator · Stanford Health Care · Oct 3, 2024
Care Team
J. Torres, RN
Care Navigator · Supervising
Oct 3, 2024Navigator-supervised · G0296
Compliance
CMS NCD 210.14 — CompleteUSPSTF 2021 Grade B metG0296 billing code ready
LDCT order armed · Claim-ready
Artemis Assist
Note auto-drafted. J. Torres reviews and approves in under 60 seconds.
Zero new documentation burden.
Artemis — Specificity Gate · Three-Source Verification
Three independent sources must agree before any order is armed
EHR
Structured EHR
Age 64, female
Former smoker on record
Demographics · Problem list
✓
NLP
Unstructured NLP
Smoking history identified
Pack-years: not in note
Progress note · 2024-03-14
✓
SDM
SDM Completed
23 pack-years · quit 2019
Consent: yes · RN validated
Maya + J. Torres, RN · G0296 armed
✓
Specificity gate: cleared. LDCT order armed.
23 pack-years confirmed — exceeds USPSTF 2021 threshold of 20. Claim will not be denied.
Model score alone never drives clinical action. Every decision is physician-reviewable.
SOC 2 Type IIHIPAA BAAFull audit trail
HealthOS EHR — Orders — Chen, Maria A. — MRN 4781-2099
Chen, Maria A. — MRN 4781-2099
Dr. K. Yamada · Stanford Health Care
Summary
Progress Notes
Orders
Results
Med List
Order Types
Pending Signature (1)
Active Orders
Completed
Medications
Quick Actions
New Order
Sign All
Artemis
1 order ready
Chen, Maria A.
DOB: 04/11/1962 (64 yrs)
MRN: 4781-2099
PCP: Dr. K. Yamada
Insurance: Medicare Advantage
AWAITING SIGNATURE · 1 ORDER
LDCT Lung Cancer Screening
Low-Dose CT · Radiology · Preventive
Pending Signature
Ordered byArtemis AI — incident-to Dr. K. Yamada
IndicationLung cancer screening · USPSTF 2021 Grade B · 23 pack-years confirmed
Facility / timeStanford Radiology · Oct 3, 2024 · 9:30 AM
SDM statusG0296 eligible · J. Torres, RN validated · CMS NCD 210.14 complete
Billing codes71271 (LDCT) + G0296 (SDM) · Medicare covered · $0 patient copay
SDM documentation attached ↗
Dr. K. Yamada · PCP
Pending order.
One click to sign.
Artemis pre-populates the LDCT order, SDM note, and billing codes. Dr. Yamada reviews and clicks Sign — no chart work added.
Artemis — Longitudinal Care · Maria Chen
What happened to Maria after her LDCT
Artemis monitors outcomes and surfaces follow-up gaps — automatically.
Oct 3, 2024
LDCT Screening Completed
6 mm pulmonary nodule detected, right upper lobe · Lung-RADS 3 — short-term follow-up recommended
Nov 5, 2024
Follow-up CT — Nodule Growth
Nodule increased to 9 mm · Lung-RADS 4B — biopsy recommended
Nov 22, 2024
PET/CT — Hypermetabolic Activity
SUV max 4.2 in right upper lobe · High suspicion for malignancy
Dec 4, 2024
CT-Guided Biopsy — Malignancy Confirmed
Adenocarcinoma · Stage IA2 · Resectable · No lymph node involvement
Dec 19, 2024
VATS Lobectomy — Successful Resection
R0 margins · No adjuvant therapy required · 5-year survival rate: 92%
2025 →
Surveillance — No Evidence of Disease
Q6-month CT scans · Artemis tracking adherence and follow-up gaps
🩺
Stage I. Caught early. Survivable.
Without Artemis, Maria's nodule might not have been found for years — Stage I has a 92% 5-year survival rate vs. 10% at Stage IV.
Artemis — Downstream Revenue · Population View
$0
Estimated downstream revenue
847 activated pathways · avg. $12K per patient
0
Stage I–II catches vs. late-stage without screening
Early detection · avg. 5-yr survival 88%
PatientPathway triggeredRevenue generatedStatus
Chen, Maria · 64F SDM → LDCT → Biopsy → VATS $24,301 ● Active
Porter, James · 71M SDM → LDCT → Annual $519 ● Active
Brown, Patricia · 63F SDM → LDCT → Follow-up CT $1,361 ● Active
Hall, Donald · 73M SDM → LDCT → Annual $519 ◌ Scheduled
Harris, Barbara · 61F SDM → LDCT → PET/CT $3,329 ● Active
Lewis, Nancy · 70F SDM → LDCT → Annual $519 ◌ Scheduled
Nguyen, Linh · 62F SDM → LDCT → Follow-up CT $1,361 ● Active
Maria Chen · Care Pathway Revenue
Procedures billed after Artemis-initiated LDCT screening
CodeDescriptionMedicare rate
G0296SDM counseling visit$121
71271LDCT screening, annual$398
71250CT chest with contrast (follow-up)$842
78816PET/CT whole body$2,810
32408CT-guided core needle biopsy$890
32663VATS lobectomy$18,420
99213 ×4Office follow-up visits (Year 1)$820
Total · Maria Chen pathway$24,301
Revenue generated by the health system — not Artemis. Artemis creates the access event that makes it possible.
Artemis — System Capabilities
What Artemis delivers
A win for patients. A win for the system.
0
Physician clicks added per completed workflow
vs. dozens of manual steps today
0
More patients screened vs. status quo
industry avg: 17% screening rate
0
SDM completion rate
industry avg: 60%
0
Days from outreach to first scan
vs. 30+ day benchmark
0
Annual screening adherence
industry avg: 37%
Better outcomes for patients. · More revenue for the health system.

Artemis turns eligible-but-missed
into screened-and-paid.

No new staff. No physician burden. No missed revenue. Just patients who finally get the care they deserve.

Artemis
artemis.health · request a demo

All data is synthetic and used for demonstration purposes only. All individuals depicted are fictional.